<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Nutr Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Nutr Sci</journal-id><journal-id journal-id-type="publisher-id">JNS</journal-id><journal-title-group><journal-title>Journal of Nutritional Science</journal-title></journal-title-group><issn pub-type="epub">2048-6790</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25191600</article-id><article-id pub-id-type="pmc">4153077</article-id><article-id pub-id-type="doi">10.1017/jns.2013.31</article-id><article-id pub-id-type="pii">S2048679013000311</article-id><article-id pub-id-type="publisher-id">00031</article-id><article-categories><subj-group subj-group-type="heading"><subject>Nutritional Immunology</subject></subj-group></article-categories><title-group><article-title>Consumption of <italic>Bifidobacterium lactis</italic> Bi-07 by healthy
elderly adults enhances phagocytic activity of monocytes and granulocytes</article-title><alt-title alt-title-type="left-running">Sujira Maneerat <italic>et al.</italic></alt-title><alt-title alt-title-type="right-running">Consumption of <italic>Bifidobacterium
lactis</italic> Bi-07 by healthy elderly adults enhances phagocytic activity of monocytes
and granulocytes</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Maneerat</surname><given-names>Sujira</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lehtinen</surname><given-names>Markus J.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Childs</surname><given-names>Caroline E.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Forssten</surname><given-names>Sofia D.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Alhoniemi</surname><given-names>Esa</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tiphaine</surname><given-names>Milin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yaqoob</surname><given-names>Parveen</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ouwehand</surname><given-names>Arthur C.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rastall</surname><given-names>Robert A.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Food and Nutritional
Sciences</addr-line>, <institution>University of Reading</institution>, <addr-line>Reading
RG6 6AP</addr-line>, <country>UK</country></aff><aff id="aff2"><label>2</label><addr-line>Active Nutrition, DuPont Nutrition and Health,
Danisco Sweeteners OY Sokeritehtaantie 20, 02460 Kantvik</addr-line>,
<country>Finland</country></aff><aff id="aff3"><label>3</label><institution>Pharmatest Services Ltd</institution>,
<addr-line>It&#x000e4;inen Pitk&#x000e4;katu 4 C, FI-20520</addr-line><country>Finland</country></aff><author-notes><corresp id="cor1"><label>*</label><addr-line><bold>Corresponding author:</bold> Dr Caroline
Childs</addr-line>, fax <fax>+44 23 8079 4221</fax>, email <email>c.e.childs@soton.ac.uk</email></corresp></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>2</day><month>1</month><year>2014</year></pub-date><volume>2</volume><elocation-id>e44</elocation-id><history><date date-type="received"><day>29</day><month>4</month><year>2013</year></date><date date-type="rev-recd"><day>19</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>03</day><month>10</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access"><license-p><!--CREATIVE COMMONS-->The online version of this article is published within an Open Access
environment subject to the conditions of the Creative Commons Attribution license
&#x0003c;<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="S2048679013000311a.pdf"/><abstract abstract-type="normal"><p>Elderly adults have alterations in their gut microbiota and immune functions that are
associated with higher susceptibility to infections and metabolic disorders. Probiotics
and prebiotics, and their synbiotic combinations are food supplements that have been shown
to improve both gut and immune function. The objective of this randomised, double-blind,
placebo-controlled, cross-over human clinical trial was to study immune function and the
gut microbiota in healthy elderly adults. Volunteers (<italic>n</italic> 37) consumed
prebiotic galacto-oligosaccharides (GOS; 8&#x000a0;g/d), probiotic <italic>Bifidobacterium
lactis</italic> Bi-07 (Bi-07; 10<sup>9</sup> colony-forming units/d), their combination
(Bi-07&#x000a0;+&#x000a0;GOS) and maltodextrin control (8&#x000a0;g/d) in four 3-week periods separated by 4-week
wash-out periods. Immune function was analysed by determining the phagocytic and oxidative
burst activity of monocytes and granulocytes, whole-blood response to lipopolysaccharide,
plasma chemokine concentrations and salivary IgA levels. Gut microbiota composition and
faecal SCFA content were determined using 16S ribosomal RNA fluorescence <italic>in
situ</italic> hybridisation and HPLC, respectively. Primary statistical analyses indicated
the presence of carry-over effects and thus measurements from only the first
supplementation period were considered valid. Subsequent statistical analysis showed that
consumption of Bi-07 improved the phagocytic activity of monocytes
(<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;001) and granulocytes (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;02). Other
parameters were unchanged. We have for the first time shown that the probiotic Bi-07 may
provide health benefits to elderly individuals by improving the phagocytic activity of
monocytes and granulocytes. The present results also suggest that in the elderly, the
effects of some probiotics and prebiotics may last longer than in adults.</p></abstract><kwd-group><title>Key words</title><kwd>Clinical trials</kwd><kwd>Elderly adults</kwd><kwd>Probiotics</kwd><kwd>Prebiotics</kwd></kwd-group><kwd-group kwd-group-type="abbreviations"><title>Abbreviations</title><kwd>Bi-07, <italic>Bifidobacterium animalis</italic> subsp. <italic>lactis</italic> Bi-07</kwd><kwd>GOS, galacto-oligosaccharide</kwd><kwd>IFN, interferon</kwd><kwd>LPS, lipopolysaccharide</kwd><kwd>ROS, reactive oxygen species</kwd></kwd-group><counts><fig-count count="3"/><table-count count="3"/><ref-count count="49"/><page-count count="10"/></counts></article-meta></front><body><p>Of the population of Europe, 20 % are elderly (aged&#x000a0;&#x0003e;&#x000a0;65 years) and this is predicted
to increase to 25 % by 2020 according to the WHO. As individuals age, changes to the
physiology and function of the gastrointestinal tract and immune system status
occur<sup>(</sup><xref rid="ref1" ref-type="bibr">
<sup>1</sup>
</xref><sup>)</sup>. These changes are associated with increased susceptibility to infections,
metabolic disorders and frailty that have significant impact on the quality of life in elderly
individuals and healthcare costs to society.</p><p>Although age-related changes have been shown in the composition, biodiversity and metabolic
activities of the gut microbiota, clear patterns of changes are still obscure due to the
impact of the environment and host on the microbiota<sup>(</sup><xref rid="ref2" ref-type="bibr">
<sup>2</sup>
</xref><sup>&#x02013;</sup><xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref><sup>)</sup>. For example, the amount of <italic>Bacteroides</italic> in the intestine
has been shown to both increase and decrease in elderly subjects depending on the population
studied<sup>(</sup><xref rid="ref5" ref-type="bibr">
<sup>5</sup>
</xref><sup>&#x02013;</sup><xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref><sup>)</sup>. It is, however, well established that with age the amount of facultative
anaerobes increases, such as opportunistic pathogens found in Proteobacteria and
Bacilli<sup>(</sup><xref rid="ref5" ref-type="bibr">
<sup>5</sup>
</xref><sup>&#x02013;</sup><xref rid="ref9" ref-type="bibr">
<sup>9</sup>
</xref><sup>)</sup>. Also, the number and diversity of beneficial bifidobacteria have been
shown to decline in some studies, indicating that a detrimental shift in the balance of
microbial species occurs with ageing<sup>(</sup><xref rid="ref1" ref-type="bibr">
<sup>1</sup>
</xref><sup>,</sup><xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref><sup>)</sup>.</p><p>Changes in the microbiota of the elderly are associated with changes in the immune system
status characterised by higher production of pro-inflammatory cytokines<sup>(</sup><xref rid="ref3" ref-type="bibr">
<sup>3</sup>
</xref><sup>)</sup>. It was recently shown that higher amounts of Bacilli and Proteobacteria
in the intestine are associated with increased IL-6 and IL-8 plasma levels in the
elderly<sup>(</sup><xref rid="ref3" ref-type="bibr">
<sup>3</sup>
</xref><sup>)</sup>. Despite the increased levels of pro-inflammatory cytokines, it seems that
the reactivity of the innate and adaptive immune systems in the elderly is poorer. <italic>In
vivo</italic> these findings are perhaps best highlighted by low vaccination responses that
lead to higher susceptibility to infections<sup>(</sup><xref rid="ref10" ref-type="bibr">
<sup>10</sup>
</xref><sup>,</sup><xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref><sup>)</sup>. On a mechanism level, it has been shown that ageing decreases toll-like
receptor (TLR) signalling. For example, lipopolysaccharide (LPS) signalling through TLR4 is
impaired, leading to decreased cytokine production and immune function<sup>(</sup><xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref><sup>)</sup> that could explain the reduced phagocytic capacity of neutrophils in the
elderly<sup>(</sup><xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref><sup>,</sup><xref rid="ref13" ref-type="bibr">
<sup>13</sup>
</xref><sup>)</sup>.</p><p>An appealing approach to modulate gut microbiota, poor immune response and detrimental
effects of the ageing population is through the use of dietary interventions that have an
impact on both the gut microbiota and immune function. Probiotics and prebiotics are widely
accepted nutritional supplements that have beneficial effects on both microbiota composition
and potentially the immune system in the elderly<sup>(</sup><xref rid="ref14" ref-type="bibr">
<sup>14</sup>
</xref><sup>&#x02013;</sup><xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref><sup>)</sup>. Probiotics were defined in 2001 by an FAO/WHO workgroup as &#x02018;live
microorganisms which when administered in adequate amounts confer a health benefit on the
host&#x02019;. A prebiotic is defined as &#x02018;a selectively fermented ingredient that results in specific
changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring
benefit(s) upon host health&#x02019;<sup>(</sup><xref rid="ref17" ref-type="bibr">
<sup>17</sup>
</xref><sup>)</sup>. Prebiotics are complex oligosaccharides such as galacto-oligosaccharides
(GOS), inulin and fructo-oligosaccharides that are preferentially fermented by health-positive
bacteria<sup>(</sup><xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref><sup>&#x02013;</sup><xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref><sup>)</sup>. This leads to changes in the metabolism of the microbiota and in higher
intestinal concentrations of beneficial SCFA<sup>(</sup><xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref><sup>)</sup>. Only a few clinical trials have compared the effects of probiotics,
prebiotics and their synbiotic combinations in a single trial. In a recent study it was
concluded that changes to microbiota were different in a resistant starch and
<italic>Bifidobacterium lactis</italic> synbiotic group than in prebiotic or probiotic
groups in patients with colorectal cancer<sup>(</sup><xref rid="ref22" ref-type="bibr">
<sup>22</sup>
</xref><sup>)</sup>. Another trial concluded that synbiotic (psyllium and <italic>B.
longum</italic>) administration improved the quality of life of ulcerative colitis patients
and decreased plasma C-reactive protein, but this was not observed in probiotic or prebiotic
groups<sup>(</sup><xref rid="ref23" ref-type="bibr">
<sup>23</sup>
</xref><sup>)</sup>. In addition, in probiotic and prebiotic groups there were independent
effects on emotional and bowel function. These studies suggest that synbiotic effects may not
be additive, although a study where GOS, <italic>B. lactis</italic> Bb-12 and their synbiotic
were administered to healthy adults suggested that the synbiotic increases intestinal
bifidobacteria numbers compared with single products<sup>(</sup><xref rid="ref24" ref-type="bibr">
<sup>24</sup>
</xref><sup>)</sup>.</p><p>Consumption of probiotic <italic>B. lactis</italic> strains and GOS has been shown to
increase the number of bifidobacteria and to improve phagocytic activity in elderly adults
(<italic>B. lactis</italic> HN019 and <italic>trans</italic>-GOS)<sup>(</sup><xref rid="ref24" ref-type="bibr">
<sup>24</sup>
</xref><sup>&#x02013;</sup><xref rid="ref26" ref-type="bibr">
<sup>26</sup>
</xref><sup>)</sup>, indicating that consumption of <italic>B. lactis</italic>, GOS and their
synbiotic combination could improve health. This clinical trial aims to study the impact of
probiotic <italic>B. animalis</italic> subsp. <italic>lactis</italic> Bi-07 (Bi-07), prebiotic
GOS, synbiotic Bi-07&#x000a0;+&#x000a0;GOS and maltodextrin control on gut microbiota and the immune system in
healthy elderly adults. The study was designed to follow supplementation-induced changes in
microbiota by analysing marker bacterial groups and SCFA from faecal samples. Changes in
inflammatory status and immune system responsiveness by the supplementation were analysed by
measuring the concentration of inflammatory chemokines in plasma and the responsiveness of
isolated peripheral blood mononuclear cells to LPS, respectively. Furthermore, phagocytic and
oxidative burst activity of monocytes and granulocytes was analysed to associate changes in
microbiota and immune cell responsiveness with the function of phagocytic cells.</p><sec id="sec1"><title>Experimental methods</title><sec id="sec1-1"><title>Trial design</title><p>A total of forty-one healthy elderly volunteers were screened for inclusion to trial. Of
these, forty were found to be eligible for the study and were randomly divided into four
groups. A double-blinded, placebo-controlled, randomised cross-over study was designed
where volunteers received maltodextrin (8&#x000a0;g/d; Syral), prebiotic GOS (8&#x000a0;g/d; Danisco),
probiotic (Bi-07; 10<sup>9</sup> colony-forming units/d; Danisco) and synbiotic
GOS&#x000a0;+&#x000a0;Bi-07 (8&#x000a0;g GOS/d and 10<sup>9</sup> colony-forming units Bi-07/d). The daily
portions were based on dose&#x02013;response clinical studies showing that an 8&#x000a0;g portion of GOS
has a bifidogenic effect<sup>(</sup><xref rid="ref27" ref-type="bibr">
<sup>27</sup>
</xref><sup>)</sup> and that 10<sup>9</sup> colony-forming units of <italic>B.
lactis</italic> induce changes in elderly microflora<sup>(</sup><xref rid="ref28" ref-type="bibr">
<sup>28</sup>
</xref><sup>)</sup>. Volunteers were randomised to groups that consumed the study products
in a predefined order: group 1, prebiotic&#x02013;synbiotic&#x02013;maltodextrin&#x02013;probiotic; group 2,
synbiotic&#x02013;maltodextrin&#x02013;probiotic&#x02013;prebiotic; group 3,
maltodextrin&#x02013;probiotic&#x02013;prebiotic&#x02013;synbiotic; group 4,
probiotic&#x02013;prebiotic&#x02013;synbiotic&#x02013;maltodextrin. Supplements were provided for 21 d, with a 28
d wash-out period that has been effective in previous studies with <italic>B.
lactis</italic> and GOS<sup>(</sup><xref rid="ref24" ref-type="bibr">
<sup>24</sup>
</xref><sup>,</sup><xref rid="ref25" ref-type="bibr">
<sup>25</sup>
</xref><sup>,</sup><xref rid="ref27" ref-type="bibr">
<sup>27</sup>
</xref><sup>)</sup> (<xref ref-type="fig" rid="fig01">Fig. 1</xref>). Compliance was not
measured. The trial was registered at Clinicaltrials.gov as NCT01586247. <fig id="fig01" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Schematic overview of the study design. MDX, maltodextrin; GOS,
galacto-oligosaccharides; Bi-07, <italic>Bifidobacterium animalis</italic> subsp.
<italic>lactis</italic> Bi-07.</p></caption><graphic xlink:href="S2048679013000311_fig1"/></fig></p></sec><sec id="sec1-2"><title>Volunteers</title><p>The present study was conducted according to guidelines laid down in the Declaration of
Helsinki and all procedures involving human subjects were approved by the Research Ethics
Committee of the University of Reading. Written informed consent was obtained from all
subjects. Volunteers were recruited from the Reading area. Inclusion criteria were: a
signed consent form, age over 60 years, not in residential care, and good general health
as determined by medical questionnaires. Exclusion criteria included evidence of physical
or mental disease or planned major surgery or use of antibiotics within the previous 6
months. Subject characteristics are described in <xref ref-type="table" rid="tab01">Table
1</xref>. Volunteers attended study appointments before and after each treatment and
wash-out period. At study appointments, anthropometric measurements were recorded (weight,
blood pressure, waist circumference) and volunteers provided a fasted blood sample
(collected into heparinised tubes), and samples of saliva and faeces (<xref ref-type="fig" rid="fig01">Fig. 1</xref>). <table-wrap id="tab01" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline characteristics of volunteers in a double-blind, placebo-controlled,
randomised cross-over study of a candidate prebiotic (galacto-oligosaccharides; GOS;
8&#x000a0;g/d), probiotic (<italic>Bifidobacterium animalis</italic> subsp.
<italic>lactis</italic> Bi-07 (Bi-07); 10<sup>9</sup> colony-forming units/d) or
synbiotic (GOS&#x000a0;+&#x000a0;Bi-07)</p><p>(Mean values with their standard errors, or number of subjects)</p></caption><alternatives><graphic xlink:href="S2048679013000311_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Maltodextrin (<italic>n</italic> 9)</th><th align="center" colspan="2" rowspan="1">Prebiotic (<italic>n</italic> 9)</th><th align="center" colspan="2" rowspan="1">Probiotic (<italic>n</italic> 8)</th><th align="center" colspan="2" rowspan="1">Synbiotic (<italic>n</italic> 10)</th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex (<italic>n</italic>)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x000a0;Male</td><td align="center" colspan="2" rowspan="1">4</td><td align="center" colspan="2" rowspan="1">3</td><td align="center" colspan="2" rowspan="1">5</td><td align="center" colspan="2" rowspan="1">5</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x000a0;Female</td><td align="center" colspan="2" rowspan="1">5</td><td align="center" colspan="2" rowspan="1">6</td><td align="center" colspan="2" rowspan="1">3</td><td align="center" colspan="2" rowspan="1">5</td><td rowspan="1" colspan="1">0&#x000b7;69</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">63&#x000b7;0<sup>a</sup></td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">70&#x000b7;7<sup>b</sup></td><td rowspan="1" colspan="1">0&#x000b7;69</td><td rowspan="1" colspan="1">64&#x000b7;6<sup>a</sup></td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">70&#x000b7;5<sup>b</sup></td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">&#x0003c;0&#x000b7;001</td></tr><tr><td rowspan="1" colspan="1">Weight (kg)</td><td rowspan="1" colspan="1">76&#x000b7;5</td><td rowspan="1" colspan="1">4&#x000b7;5</td><td rowspan="1" colspan="1">74&#x000b7;5</td><td rowspan="1" colspan="1">3&#x000b7;3</td><td rowspan="1" colspan="1">73&#x000b7;8</td><td rowspan="1" colspan="1">5&#x000b7;4</td><td rowspan="1" colspan="1">75&#x000b7;0</td><td rowspan="1" colspan="1">4&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;98</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">25&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">28&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;1</td><td rowspan="1" colspan="1">25&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;2</td><td rowspan="1" colspan="1">25&#x000b7;2</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;27</td></tr><tr><td rowspan="1" colspan="1">Plasma cholesterol (m<sc>m</sc>)</td><td rowspan="1" colspan="1">5&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">5&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">5&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">6&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;66</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p><sup>a,b</sup> Mean values within a row with unlike superscript letters were
significantly different (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;05).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec1-3"><title>Study products</title><p>The GOS product was synthesised at 55&#x000b0;C (pH 5&#x000b7;0) by 50 acid lactase units (ALU)
&#x003b2;-galactosidase-1/g from <italic>Aspergillus oryzae</italic> GC288 using 55 % (w/v)
lactose (Dairy Crest) as a substrate. The GOS product yield was 32&#x000b7;45 % (w/w). The product
had predominantly Gal(&#x003b2;1&#x02013;6), Gal(&#x003b2;1&#x02013;4) and Gal(&#x003b2;1&#x02013;3) linkages. Bi-07 (ATCC SD5220;
American Type Culture Collection) was produced according to good manufacturing practice at
the Madison plant by Danisco. The maltodextrin was generously provided by Syral. The
products were consumed daily by the subjects as provided in individual daily dose sachets
in powder form.</p></sec><sec id="sec1-4"><title>Sample size determination and randomisation</title><p>The study group size was estimated by least standardised difference (LSD) using expected
changes in the microbial population and faeces as the primary outcome. On the basis of a 5
% significance level, a power of 95 % for detecting the main effect and two-factor
interactions, with a standardised size effect of 0&#x000b7;85 or more, a sample size of eight per
treatment per group was required. A total of ten per group were included in the study to
allow for potential study &#x02018;drop-out&#x02019;. Blinding was done by Danisco and randomisation to
study groups 1&#x02013;4 by the investigators.</p></sec><sec id="sec1-5"><title>Statistical analysis</title><p>The data from the cross-over study were analysed using linear fixed-effects models with
fixed effect terms for the presence/absence of prebiotic/probiotic treatment and their
interaction (i.e. a 2&#x000a0;&#x000d7;&#x000a0;2 factorial approach), and a baseline regression coefficient
accounting for individual baseline differences between the subjects. Based on the residual
analysis, some variables were transformed using logarithmic, square root or power
transformations. All the treatments related to statistically significant factors in the
linear models (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;05) were further statistically compared using
contrasts for the linear models. The number of contrasts depended on the statistically
significant terms, and the obtained <italic>P</italic> values were adjusted for multiple
comparisons using a single-step algorithm.</p><p>The linear model analyses were conducted with R: A Language and Environment for
Statistical Computing (version 2.14.2; R Development Core Team) using packages nlme:
Linear and Nonlinear Mixed Effects Models (version 3.1-103; J. Pinheiro, D. Bates, S.
DebRoy, D. Sarkar and R Development Core Team), and multcomp (version
1.2.12)<sup>(</sup><xref rid="ref29" ref-type="bibr">
<sup>29</sup>
</xref><sup>)</sup>.</p></sec><sec id="sec1-6"><title>Phagocytosis and oxidative burst</title><p>Phagocytosis and oxidative burst by monocytes and granulocytes were determined in fresh
(4&#x02013;6&#x000a0;h) heparinised whole-blood samples using PHAGOTEST<sup>&#x000ae;</sup> and
BURSTTEST<sup>&#x000ae;</sup> (ORPEGEN Pharma) in accordance with the manufacturer's instructions.
<italic>Escherichia coli</italic>, provided by the manufacturer, were opsonised with
complement and immunoglobulins using pooled sera, and were labelled with fluorescein
isothiocyanate (FITC). In brief, <italic>E. coli</italic> were incubated for 10&#x000a0;min in
heparinised whole blood at 37&#x000b0;C. Phagocytosis was stopped by placing the sample on ice and
by adding a solution that quenches extracellularly bound FITC&#x02013;<italic>E. coli</italic>.
Erythrocytes were lysed and sample washed. Using a flow cytometer (FACSCalibur, BD
Biosciences), monocytes and granulocytes were identified based upon their characteristic
appearance on a FSC/SSC (forward scatter <italic>versus</italic> side scatter) plot. The
percentages of phagocytes that had ingested bacteria (fluorescent/total) and had
phagocytic activity (number of bacteria per cell as determined by mean fluorescence
intensity) were determined.</p><p>In BURSTTEST<sup>&#x000ae;</sup>, complement and immunoglobulin-opsonised <italic>E.
coli</italic> as provided by the manufacturer were incubated with heparinised whole blood
for 10&#x000a0;min at 37&#x000b0;C. Fluorogenic dihydrorhodoamine-123, which reacts with reactive oxygen
species (ROS), was added to the sample and incubated for 10&#x000a0;min at 37&#x000b0;C. The reaction was
stopped by adding an erythrocyte-lysing solution. After washing, the monocytes and
granulocytes were identified by means of an FSC/SSC plot using a flow cytometer
(FACSCalibur; BD Biosciences). The production of reactive oxygen metabolites within
monocytes and granulocytes was determined by counting the percentage of fluorescent cells
and their mean fluorescence intensity, which correlates with ROS production.</p></sec><sec id="sec1-7"><title>Immune assays</title><p>Cytokine and chemokine concentrations were determined using commercially available
bead-arrays from BenderMedSystems which both utilise sandwich ELISA technology. All immune
assays were conducted to conform to an intra-assay CV of &#x0003c;10 % and an inter-assay
CV of &#x0003c;20 %. Sample concentrations were calculated using an eight-point standard
curve.</p><p>LPS-stimulated cytokine production was analysed in 1/10 diluted whole blood. Roswell Park
Memorial Institute (RPMI)-1640 media containing HEPES and <sc>l</sc>-glutamine (Lonza) was
used, to which streptomycin (1&#x000a0;mg/ml) and penicillin (62&#x000b7;5&#x000a0;&#x000b5;g/ml) were added. Cultures
were incubated for 24&#x000a0;h in the presence of LPS from <italic>E. coli</italic> O111:B4
(1&#x000a0;&#x000b5;g/ml; Sigma Aldrich). Culture supernatant fractions were assessed for cytokine
production using a Th1/Th2 cytokine array (Bender MedSystems) in accordance with the
manufacturer's instructions. This array includes interferon (IFN)-&#x003b3;, IL-1&#x003b2;, IL-2, IL-4,
IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF-&#x003b1; and TNF-&#x003b2;. The levels of IL-2, IL-4, IL-5,
IL-12p70, and TNF-&#x003b2; were below detection levels in most of the samples (data not
presented).</p><p>Plasma chemokines were assessed using a human chemokine 6-plex kit (Bender MedSystems) in
accordance with the manufacturer's instructions. This array includes granulocyte-colony
stimulating factor (G-CSF), monocyte chemotactic protein-1 (MCP-1), monokine induced by
interferon-&#x003b3; (MIG), macrophage inflammatory protein 1-&#x003b1; (MIP1-&#x003b1;) and macrophage
inflammatory protein 1-&#x003b2; (MIP1-&#x003b2;).</p><p>Saliva samples were collected by expectoration in the morning by fasted participants.
Samples were centrifuged at 1000 <bold><italic>g</italic></bold> for 10&#x000a0;min and supernatant fractions stored at &#x02013;20&#x000b0;C before analysis. Salivary IgA
content was determined by sandwich ELISA (Immunodiagnostik) in accordance with the
manufacturer's instructions.</p></sec><sec id="sec1-8"><title>Faecal sample processing</title><p>Freshly voided faecal samples were collected in sterile plastic containers. Samples were
stored at room temperature under anaerobic conditions before processing, which typically
commenced within 4&#x000a0;h of sample receipt. Samples for use in faecal dry weight and IgA
assays were stored at &#x02013;20&#x000b0;C, and samples for quantitative PCR and enumeration of total
bacteria by flow cytometry stored at &#x02013;80&#x000b0;C. Remaining faecal samples were diluted 1 in 10
(w/w) in PBS (0&#x000b7;1 <sc>m</sc>; pH 7&#x000b7;0) and homogenised in a Stomacher 400 (Seward) for
2&#x000a0;min at normal speed (460 paddle beats per min). A 15&#x000a0;ml sample of faecal slurry was
vortexed with 2&#x000a0;g of 3-mm diameter glass beads (VWR International) and then centrifuged to
remove particulate matter (1500 <bold><italic>g</italic></bold>; 2&#x000a0;min). The supernatant fraction was collected for use in SCFA analysis and
assessment of genus-level changes in the gut microbiota by fluorescence <italic>in
situ</italic> hybridisation with 16S ribosomal RNA targeted oligonucleotide probes.</p></sec><sec id="sec1-9"><title>Fluorescence <italic>in situ</italic> hybridisation</title><p>The faecal slurry supernatant fraction was fixed in paraformaldehyde (1:4 (v/v) in 4 %
paraformaldehyde in 0&#x000b7;1 <sc>m</sc>-PBS, pH 7&#x000b7;2) for 4&#x000a0;h at 4&#x000b0;C, centrifuged (13 000 <bold><italic>g</italic></bold>; 5&#x000a0;min), washed twice with 0&#x000b7;1 <sc>m</sc>-PBS, re-suspended in 1:1 PBS&#x02013;ethanol and
stored at &#x02013;20&#x000b0;C. Oligonucleotide probes used were Cy-3 labelled and synthesised by
Sigma-Aldrich. Probes used were Bif164, Bac303, Chis150, Lab158 and ATO291, Erec482,
Fprau655, Enter1432 and Strc493 specific for <italic>Bifidobacterium</italic> spp.,
<italic>Bacteroides&#x02013;Prevotella</italic> group, <italic>Clostridium</italic> clusters I
and II (including <italic>Clostridium perfringens</italic> and <italic>C.
histolyticum</italic>), <italic>Lactobacillus&#x02013;Enterococcus</italic> subgroup,
<italic>Atopobium</italic> cluster, <italic>Eubacterium rectale</italic>&#x02013;<italic>Blautia
coccoides</italic> group, <italic>Faecalibacterium</italic> cluster,
<italic>Enterobacterium</italic> group and <italic>Streptococcus</italic>
group&#x02013;<italic>Lactococcus</italic>, respectively<sup>(</sup><xref rid="ref30" ref-type="bibr">
<sup>30</sup>
</xref><sup>&#x02013;</sup><xref rid="ref36" ref-type="bibr">
<sup>36</sup>
</xref><sup>)</sup>. Samples were hybridised as described by Costabile <italic>et
al.</italic><sup>(</sup><xref rid="ref37" ref-type="bibr">
<sup>37</sup>
</xref><sup>)</sup>. Data are expressed as log<sub>10</sub> counts per g dry faeces.</p></sec><sec id="sec1-10"><title>Quantification of <italic>Bifidobacterium lactis</italic></title><p>DNA was extracted from the faecal samples with the use of the QIAamp DNA stool Mini kit
(Qiagen) following the manufacturer's instructions. Quantitative PCR was used for
quantification of <italic>B. lactis</italic> using the FAST SYBR green methodology
(Applied Biosystems) in a total volume of 25 &#x000b5;l containing 1&#x000a0;ng of template DNA and 250
n<sc>m</sc> of the forward primer Blact_1<sup>(</sup><xref rid="ref38" ref-type="bibr">
<sup>38</sup>
</xref><sup>)</sup> and reverse primer Bflact5<sup>(</sup><xref rid="ref39" ref-type="bibr">
<sup>39</sup>
</xref><sup>)</sup>. The amplification and detection of DNA were performed with an ABI
7500 sequencing detection system (Applied Biosystems). To obtain standard curves, a
10-fold dilution series ranging from 10 pg to 10&#x000a0;ng of DNA from the bacterial standard
cultures was included in the PCR assays. For determination of DNA, triplicate samples were
used, and the mean quantity per g wet weight was calculated.</p></sec><sec id="sec1-11"><title>Organic acids</title><p>Filter-sterilised samples (1&#x000a0;ml) of faecal slurry (10 % (w/v) dilution of freshly voided
faeces in PBS; pH 7&#x000b7;0) were used to determine faecal concentrations of organic acids
including acetic acid, propionic acid, <italic>i</italic>-butyric acid,
<italic>n</italic>-butyric acid, <italic>i</italic>-valeric acid,
<italic>n</italic>-valeric acid, <italic>n</italic>-caproic acid and
<sc>d-</sc>/<sc>l</sc>-lactic acid by HPLC. The column was an ion-exclusion REZEX-ROA
organic acid column (7&#x000b7;8&#x000a0;&#x000d7;&#x000a0;300&#x000a0;nm; Phenomenex) maintained at 85&#x000b0;C. The eluent was
0&#x000b7;0025&#x000a0;m<sc>m</sc>-sulfuric acid in HPLC-grade water and the flow rate was 0&#x000b7;6&#x000a0;ml/min.
Quantification of the samples was obtained through calibration curves of acetic acid,
formic acid, propionic acid, butyric acid and lactic acid in concentrations between 6&#x000b7;25
and 100&#x000a0;m<sc>m</sc>.</p></sec></sec><sec sec-type="results" id="sec2"><title>Results</title><sec id="sec2-1"><title>Subject characteristics</title><p>Recruitment of forty-one subjects for the study took place in the Reading area of the UK.
Of these, forty volunteers passed the inclusion/exclusion criteria and started the trial
in March 2008; thirty-seven completed the trial in October 2009. However, one subject was
removed from the statistical analysis due to missing samples, resulting in a study size of
thirty-six subjects (see the Sample size determination and randomisation section, <xref ref-type="table" rid="tab01">Table 1</xref> and <xref ref-type="fig" rid="fig01">Fig.
1</xref>).</p></sec><sec id="sec2-2"><title>Analyses of baseline drift, carry-over effect and subject characteristics</title><p>Stability of the baseline was studied by comparing results from samples on day &#x02013;5
(baseline) and on day 0 (before first supplementation). Using independent-samples
<italic>t</italic> tests it was found that six out of forty parameters had significantly
different levels (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;05) on day 0 than on day &#x02013;5 in some
supplementation groups (<xref ref-type="table" rid="tab02">Table 2</xref>). These results
indicate that the baselines within the groups were not stable. <table-wrap id="tab02" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Parameters having baseline drift or carry-over effects</p></caption><alternatives><graphic xlink:href="S2048679013000311_tab2"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Treatment group</th><th align="center" rowspan="1" colspan="1">Baseline drift</th><th align="center" rowspan="1" colspan="1">Carry-over effect</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic>Bifidobacterium lactis</italic>
</td><td rowspan="1" colspan="1">Prebiotic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1"><italic>Bacteroides</italic>&#x02013;<italic>Prevotella</italic></td><td rowspan="1" colspan="1">Probiotic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1"><italic>Blautia
coccoides</italic>&#x02013;<italic>Eubacterium rectale</italic> cluster</td><td rowspan="1" colspan="1">Probiotic</td><td rowspan="1" colspan="1">&#x02713;</td><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1">Enterobacteria</td><td rowspan="1" colspan="1">Prebiotic</td><td rowspan="1" colspan="1">&#x02713;</td><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1"><italic>Faecalibacterium prausnitzii</italic>
cluster</td><td rowspan="1" colspan="1">Synbiotic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1"><italic>Faecalibacterium prausnitzii</italic>
cluster</td><td rowspan="1" colspan="1">Probiotic</td><td rowspan="1" colspan="1">&#x02713;</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">IL-8</td><td rowspan="1" colspan="1">Probiotic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1"><italic>Lactobacillus</italic>&#x02013;<italic>Streptococcus</italic> group</td><td rowspan="1" colspan="1">Probiotic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1">Oxidative burst activity of monocytes</td><td rowspan="1" colspan="1">Probiotic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1">Percentage of granulocytes having oxidative burst
activity</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">&#x02713;</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Percentage of monocytes having phagocytic activity</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Prebiotic</td><td rowspan="1" colspan="1">&#x02713;</td><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Probiotic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Synbiotic</td><td rowspan="1" colspan="1">&#x02713;</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Phagocytic activity of monocytes</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">&#x02713;</td><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Probiotic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02713;</td></tr><tr><td rowspan="1" colspan="1">Total bacteria</td><td rowspan="1" colspan="1">Probiotic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02713;</td></tr></tbody></table></alternatives></table-wrap></p><p>Carry-over effects are a known problem in clinical trials with a cross-over design.
Samples from day 0 (before first supplementation) and day 49 (after the first wash-out)
were analysed for similarity using independent-samples <italic>t</italic> tests. By using
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;05 as a cut-off, it was found that in eleven out of forty
parameters the values did not return to pre-supplementation levels in some groups (<xref ref-type="table" rid="tab02">Table 2</xref>). It was concluded that carry-over effects
might bias the results and thus statistical analysis was conducted for parallel groups
using results from samples obtained on day 0 (before the first supplementation) and on day
21 (after the first supplementation).</p><p>The change in study design from cross-over to parallel resulted in an unbalanced age
distribution between the study groups. Subjects in the maltodextrin and probiotic groups
were of similar age, but subjects in the prebiotic and synbiotic groups were on average
6&#x000b7;8 years younger (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;001) (<xref ref-type="table" rid="tab01">Table 1</xref>).</p></sec><sec id="sec2-3"><title>Activity of peripheral blood monocytes and granulocytes</title><p>The supplementations did not change the percentages of monocytes and granulocytes engaged
in phagocytosis compared with maltodextrin (<xref ref-type="fig" rid="fig02">Fig.
2(a)</xref> and <xref ref-type="fig" rid="fig02">2(b)</xref>); however, there was a higher
percentage of phagocytosing monocytes in the probiotic group compared with the prebiotic
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;005) group (<xref ref-type="fig" rid="fig02">Fig. 2(a)</xref>).
Phagocytic activity of monocytes in the probiotic group was higher than in the
maltodextrin (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;001) or prebiotic groups
(<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;001) (<xref ref-type="fig" rid="fig02">Fig. 2(c)</xref>).
Furthermore, a higher phagocytic activity of granulocytes was found in the probiotic
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;02) supplementation group compared with the maltodextrin group
(<xref ref-type="fig" rid="fig02">Fig. 2(d)</xref>). <fig id="fig02" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>Phagocytic activity of monocytes and granulocytes. Phagocytic activity was measured
using a flow cytometer after incubation of opsonised and fluorescence-labelled
<italic>Escherichia coli</italic> in whole blood of the subjects. Percentage of
monocytes (a) and granulocytes (b) of the total population that had phagocytosed
<italic>E. coli</italic>. Phagocytic activity of monocytes (c) and granulocytes
(d) measured as fluorescence intensity in individual cells that had phagocytosed
<italic>E. coli</italic>. Statistical differences were calculated using linear
model contrasts. Whiskers represent the minimum and maximum values; the box
represents the 25th percentile, median and 75th percentile;&#x000a0;+&#x000a0;indicates the mean
value. Mean value was significantly different from that of the maltodextrin group:
*<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;02, **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;001. Mean value was
significantly different from that of the prebiotic group:
&#x02020;<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;005, &#x02020;&#x02020;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;001.</p></caption><graphic xlink:href="S2048679013000311_fig2"/></fig></p><p>The BURSTTEST<sup>&#x000ae;</sup> assay was used to measure the presence of ROS in phagocytes
after incubation of opsonised <italic>E. coli</italic> in whole blood from the study
subjects. The proportion of monocytes and granulocytes producing ROS was not affected by
the supplementations compared with maltodextrin (<xref ref-type="fig" rid="fig03">Fig.
3(a)</xref> and <xref ref-type="fig" rid="fig03">3(b)</xref>), nor was oxidative burst
activity of these cells (<xref ref-type="fig" rid="fig03">Fig. 3(c)</xref> and <xref ref-type="fig" rid="fig03">3(d)</xref>). However, the percentage of monocytes producing
ROS in the probiotic group was higher than in the synbiotic group
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;04) (<xref ref-type="fig" rid="fig03">Fig. 3(a)</xref>). <fig id="fig03" orientation="portrait" position="float"><label>Fig. 3.</label><caption><p>Oxidative burst activity of phagocytes. Oxidative burst activity was measured using
a flow cytometer after incubation of opsonised and fluorescence-labelled
<italic>Escherichia coli</italic> in whole blood of the subjects. Percentage of
monocytes (a) and granulocytes (b) of the total population showing oxidative burst
activity. Oxidative burst activity of monocytes (c) and granulocytes (d) measured as
fluorescence intensity in individual cells that had oxidative burst activity.
Statistical differences were calculated using linear model contrasts. Whiskers
represent the minimum and maximum values; the box represents the 25th percentile,
median and 75th percentile;&#x000a0;+&#x000a0;indicates the mean value. &#x02021;Mean value was
significantly different from that of the probiotic group
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;04).</p></caption><graphic xlink:href="S2048679013000311_fig3"/></fig></p></sec><sec id="sec2-4"><title>Lipopolysaccharide stimulation of the whole blood and soluble immune markers</title><p>Immune markers were analysed from saliva, plasma, and by stimulating heparinised whole
blood with LPS. The levels of cytokines in whole blood, chemokine concentrations in plasma
and IgA levels in saliva were unaltered by the treatments (online Supplementary Table
S1).</p></sec><sec id="sec2-5"><title>Composition and metabolic function of the intestinal microbiota</title><p>Microbiota compositions of the subjects were characterised using 16S ribosomal RNA
targeted fluorescence <italic>in situ</italic> hybridisation for the selected marker
species or quantitative PCR for the determination of <italic>B. lactis</italic> (<xref ref-type="table" rid="tab03">Table 3</xref>). Composition of the microbiota did not
significantly change in any of the treatment groups. Metabolic activity of the microbiota
was measured by analysing organic acid concentrations in the faeces, but there was no
significant effect of any of the treatments (online Supplementary Table S2). <table-wrap id="tab03" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Gut microbiota of volunteers during treatment with placebo, a prebiotic
(galacto-oligosaccharides; GOS; 8&#x000a0;g/d), probiotic (<italic>Bifidobacterium
animalis</italic> subsp. <italic>lactis</italic> Bi-07 (Bi-07); 10<sup>9</sup>
colony-forming units/d) or synbiotic (GOS&#x000a0;+&#x000a0;Bi-07) at the end of the first 21 d
treatment period</p><p>(Mean values with their standard errors)</p></caption><alternatives><graphic xlink:href="S2048679013000311_tab3"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="8" rowspan="1">Treatment</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Maltodextrin (<italic>n</italic> 9)
(log<sub>10</sub> cells/g faeces)</th><th align="center" colspan="2" rowspan="1">Prebiotic (<italic>n</italic> 9)
(log<sub>10</sub> cells/g faeces)</th><th align="center" colspan="2" rowspan="1">Probiotic (<italic>n</italic> 8)
(log<sub>10</sub> cells/g faeces)</th><th align="center" colspan="2" rowspan="1">Synbiotic (<italic>n</italic> 10)
(log<sub>10</sub> cells/g faeces)</th></tr><tr><th align="left" rowspan="1" colspan="1">Bacterial group</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sem</sc>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><italic>Atopobium</italic> cluster</td><td rowspan="1" colspan="1">10&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;10</td><td rowspan="1" colspan="1">10&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;10</td><td rowspan="1" colspan="1">10&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;05</td><td rowspan="1" colspan="1">10&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;06</td></tr><tr><td rowspan="1" colspan="1"><italic>Bacteroides</italic>&#x02013;<italic>Prevotella</italic></td><td rowspan="1" colspan="1">10&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;07</td><td rowspan="1" colspan="1">10&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;15</td><td rowspan="1" colspan="1">10&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;08</td><td rowspan="1" colspan="1">10&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;08</td></tr><tr><td rowspan="1" colspan="1"><italic>Bifidobacterium</italic> group</td><td rowspan="1" colspan="1">10&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;13</td><td rowspan="1" colspan="1">9&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;20</td><td rowspan="1" colspan="1">9&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;39</td><td rowspan="1" colspan="1">9&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;13</td></tr><tr><td rowspan="1" colspan="1">
<italic>Bifidobacterium lactis</italic>
</td><td rowspan="1" colspan="1">5&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;25</td><td rowspan="1" colspan="1">6&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;22</td><td rowspan="1" colspan="1">6&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;22</td><td rowspan="1" colspan="1">6&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;30</td></tr><tr><td rowspan="1" colspan="1"><italic>Clostridium</italic> clusters I and II</td><td rowspan="1" colspan="1">8&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;24</td><td rowspan="1" colspan="1">8&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;27</td><td rowspan="1" colspan="1">8&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;43</td><td rowspan="1" colspan="1">7&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;27</td></tr><tr><td rowspan="1" colspan="1"><italic>Blautia
coccoides</italic>&#x02013;<italic>Eubacterium rectale</italic> cluster</td><td rowspan="1" colspan="1">10&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;07</td><td rowspan="1" colspan="1">10&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;10</td><td rowspan="1" colspan="1">10&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;06</td><td rowspan="1" colspan="1">10&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;06</td></tr><tr><td rowspan="1" colspan="1">Enterobacteria</td><td rowspan="1" colspan="1">9&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;31</td><td rowspan="1" colspan="1">9&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;27</td><td rowspan="1" colspan="1">9&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;41</td><td rowspan="1" colspan="1">9&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;17</td></tr><tr><td rowspan="1" colspan="1"><italic>Faecalibacterium prausnitzii</italic>
cluster</td><td rowspan="1" colspan="1">10&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;05</td><td rowspan="1" colspan="1">10&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;12</td><td rowspan="1" colspan="1">10&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;04</td><td rowspan="1" colspan="1">10&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;09</td></tr><tr><td rowspan="1" colspan="1"><italic>Lactobacillus</italic>&#x02013;<italic>Streptococcus</italic> group</td><td rowspan="1" colspan="1">9&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;24</td><td rowspan="1" colspan="1">8&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;14</td><td rowspan="1" colspan="1">9&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;16</td><td rowspan="1" colspan="1">8&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;10</td></tr><tr><td rowspan="1" colspan="1">Total bacteria</td><td rowspan="1" colspan="1">11&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;09</td><td rowspan="1" colspan="1">11&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;12</td><td rowspan="1" colspan="1">11&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;07</td><td rowspan="1" colspan="1">11&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;06</td></tr></tbody></table></alternatives></table-wrap></p></sec></sec><sec sec-type="discussion" id="sec3"><title>Discussion</title><p>A randomised placebo-controlled cross-over clinical trial was designed to study the effect
of probiotic Bi-07, prebiotic GOS or their synbiotic combination Bi-07&#x000a0;+&#x000a0;GOS on gut and
immune functions in healthy non-institutionalised elderly adults. It was found that the
baseline of some of the parameters drifted before supplementation (<xref ref-type="table" rid="tab02">Table 2</xref>), which could indicate natural fluctuation in this population.
In addition, statistical analyses of the cross-over study revealed significant carry-over
effects on indices of microbiota and immune function (<xref ref-type="table" rid="tab02">Table 2</xref>), indicating that a 4-week wash-out period was not sufficient in this
trial. In a similar study set-up, the effect of GOS syrup (8&#x000b7;1&#x000a0;g GOS/d), <italic>B.
lactis</italic> Bb-12 and their combination was studied on bifidobacteria numbers in healthy
adults. It was found that Bb-12 and Bb-12&#x000a0;+&#x000a0;GOS syrup supplementation increased
bifidobacteria amounts, but the levels returned to normal after a 2-week wash-out
period<sup>(</sup><xref rid="ref24" ref-type="bibr">
<sup>24</sup>
</xref><sup>)</sup>. Another study has also shown that after 2 weeks of wash-out, Bb-12
could be recovered from the faeces of only a few individuals, indicating transient
colonisation of <italic>B. lactis</italic> in healthy adults<sup>(</sup><xref rid="ref40" ref-type="bibr">
<sup>40</sup>
</xref><sup>)</sup>. Furthermore, two recent studies utilising pyrosequencing showed that 2
weeks after GOS supplementation the microbiota composition returned to baseline levels in
healthy adults<sup>(</sup><xref rid="ref41" ref-type="bibr">
<sup>41</sup>
</xref><sup>,</sup><xref rid="ref42" ref-type="bibr">
<sup>42</sup>
</xref><sup>)</sup>. Taken together, the results of these studies suggest that a 2-week
wash-out period is long enough in healthy adults. In the present study, however, an elderly
population was studied and it may be that probiotic and prebiotic supplementation induces
longer-lasting changes in elderly microbiota than in adults. Interestingly, in a series of
papers, elderly subjects were supplemented with <italic>B. lactis</italic> HN019 or
<italic>Lactobacillus rhamnosus</italic> HN001 and after a 3-week wash-out period several
immune indices were numerically higher than at baseline; however, unfortunately, wash-out
time points were not statistically compared with baseline<sup>(</sup><xref rid="ref25" ref-type="bibr">
<sup>25</sup>
</xref><sup>,</sup><xref rid="ref43" ref-type="bibr">
<sup>43</sup>
</xref><sup>,</sup><xref rid="ref44" ref-type="bibr">
<sup>44</sup>
</xref><sup>)</sup>.</p><p>To eliminate cross-over effects, samples from only the first supplementation period were
used in the subsequent statistical analyses, making the statistical analysis design parallel
instead of cross-over. This resulted in a higher average age in the maltodextrin and
probiotic groups compared with in the prebiotic and synbiotic groups. As it is known that
microbiota composition and immunological functions decline during ageing, the prebiotic and
synbiotic efficacy (or not) is merely speculative in the present study. However, the
comparison of the maltodextrin control with the probiotic seems to be valid.</p><p>It was found that consumption of Bi-07 improved the phagocytic activity of monocytes and
granulocytes against complement and immunoglobulin-opsonised <italic>E. coli</italic> (<xref ref-type="fig" rid="fig02">Fig. 2(c)</xref> and <xref ref-type="fig" rid="fig02">2(d)</xref>). In previously published clinical trials, enhanced phagocytosis in healthy
elderly adults has been shown for <italic>Bifidobacterium animalis</italic> subsp.
<italic>lactis</italic> HN019<sup>(</sup><xref rid="ref25" ref-type="bibr">
<sup>25</sup>
</xref><sup>,</sup><xref rid="ref45" ref-type="bibr">
<sup>45</sup>
</xref><sup>)</sup> and also in healthy adults for strains Bb-12 and HN019 of the same
species<sup>(</sup><xref rid="ref46" ref-type="bibr">
<sup>46</sup>
</xref><sup>,</sup><xref rid="ref47" ref-type="bibr">
<sup>47</sup>
</xref><sup>)</sup>. These studies support the results observed for Bi-07 in the present
trial and indicate a positive effect of <italic>B. lactis</italic> consumption on phagocytic
activity in general that could potentially lead to improved immune responses against
infective agents.</p><p>Although improved phagocytic activity was observed in the probiotic group (<xref ref-type="fig" rid="fig02">Fig. 2(c)</xref> and <xref ref-type="fig" rid="fig02">2(d)</xref>), it did not lead to higher intracellular ROS generation than what was observed
for the maltodextrin group (<xref ref-type="fig" rid="fig03">Fig. 3(c)</xref> and <xref ref-type="fig" rid="fig03">3(d)</xref>). This result was supported by similar
pro-inflammatory cytokine response levels to LPS (TNF-&#x003b1;, IFN-&#x003b3;, IL-1&#x003b2;, IL-6, and IL-8) and
stable chemokine levels in plasma (online Supplementary Table S1) in the maltodextrin and
probiotic groups. On the other hand, probiotic supplementation did not improve
anti-inflammatory IL-10 production either (online Supplementary Table S1). Previous
<italic>in vitro</italic> studies have shown that in comparison with other
<italic>Bifidobacterium</italic> and <italic>Lactobacillus</italic> strains, Bi-07 is
among the most potent inducers of IL-12p70 and IFN-&#x003b3; from human peripheral blood
monocytes<sup>(</sup><xref rid="ref48" ref-type="bibr">
<sup>48</sup>
</xref><sup>)</sup>. IFN-&#x003b3; and IL-12p70 are prototypical cytokines involved in activating
Th1-type immune responses that enhance phagocytosis and intracellular killing of microbes.
On the other hand, Bi-07 also induced a moderate amount of IL-10 from peripheral blood
mononuclear cells and protected mice from trinitrobenzene sulfonic acid (TNBS)-induced
colitis<sup>(</sup><xref rid="ref48" ref-type="bibr">
<sup>48</sup>
</xref><sup>)</sup>, which could explain the null impact on ROS generation. This type of
non-inflammatory phagocytosis is an important mechanism of maintaining homeostasis in the
gut mucosa where overt reactions to commensal microbes may lead to conditions such as
inflammatory bowel disease.</p><p>In the present randomised clinical trial on healthy elderly adults, the probiotic Bi-07 had
a positive impact on the phagocytic activity of monocytes and granulocytes in the elderly
subjects without increasing the release of ROS. Consumption of Bi-07 could potentially
improve clearance of bacteria from the body without contributing to the low-grade
inflammation observed in the elderly population<sup>(</sup><xref rid="ref49" ref-type="bibr">
<sup>49</sup>
</xref><sup>)</sup>. Thus, consumption of the probiotic Bi-07 may provide long-term health
benefits for the elderly by not contributing to inflammation-associated metabolic disorders
while enhancing the innate immune defence against infections.</p><p>The present results indicate that the wash-out time of supplementation may need to be
longer in elderly subjects than what has been shown for adults. Overall, it is likely that
the effective time of the probiotics and prebiotics on the gut microbiota and immune
function is dependent on the population, diet, and on the properties of the probiotics and
prebiotics themselves. It is clear that well-designed clinical trials on the effects of
probiotics, prebiotics and synbiotics on health are acutely needed.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data"><label>Supplementary Material</label><caption><p>Supplementary information supplied by authors.</p></caption><media xlink:href="S2048679013000311sup001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>S. M., P. Y., A. C. O. and R. A. R. designed the research; S. M., S. D. F. and M. T.
conducted the research; S. M., M. J. L., C. E. C. and E. A. analysed the data; S. M., M. J.
L. and C. E. C. wrote the paper. M. J. L. had primary responsibility for the final content.
All authors read and approved the final manuscript.</p><p>M. J. L., S. D. F. and A. C. O. are employees of DuPont Nutrition &#x00026; Health
(formerly Danisco Sweeteners OY), which manufactures and markets the tested probiotic and
provided funding for the study. None of the other authors has a conflict of interest to
report.</p></ack><notes id="nts1" notes-type="supplementary-material"><title>Supplementary material</title><p>To view supplementary material for this article, please visit <uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1017/jns.2013.31">http://dx.doi.org/10.1017/jns.2013.31</uri></p></notes><ref-list id="reflist1"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Biagi</surname><given-names>E</given-names></name>, <name><surname>Candela</surname><given-names>M</given-names></name>, <name><surname>Fairweather-Tait</surname><given-names>S</given-names></name>, <etal/> (<year>2012</year>) <article-title>Aging of the human metaorganism: the
microbial counterpart</article-title>. <source>Age (Dordr)</source><volume>34</volume>, <fpage>247</fpage>&#x02013;<lpage>267</lpage><pub-id pub-id-type="pmid">21347607</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Hopkins</surname><given-names>MJ</given-names></name>, <name><surname>Sharp</surname><given-names>R</given-names></name> &#x00026; <name><surname>Macfarlane</surname><given-names>GT</given-names></name> (<year>2001</year>) <article-title>Age and disease related changes in intestinal
bacterial populations assessed by cell culture, 16S rRNA abundance, and community
cellular fatty acid profiles</article-title>. <source>Gut</source><volume>48</volume>, <fpage>198</fpage>&#x02013;<lpage>205</lpage><pub-id pub-id-type="pmid">11156640</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Biagi</surname><given-names>E</given-names></name>, <name><surname>Nylund</surname><given-names>L</given-names></name>, <name><surname>Candela</surname><given-names>M</given-names></name>, <etal/> (<year>2010</year>) <article-title>Through ageing, and beyond: gut
microbiota and inflammatory status in seniors and centenarians</article-title>.
<source>PLoS ONE</source><volume>5</volume>, e10667.</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Claesson</surname><given-names>MJ</given-names></name>, <name><surname>Cusack</surname><given-names>S</given-names></name>, <name><surname>O'Sullivan</surname><given-names>O</given-names></name>, <etal/> (<year>2011</year>) <article-title>Composition, variability, and temporal
stability of the intestinal microbiota of the elderly</article-title>. <source>Proc Natl
Acad Sci U S A</source><volume>108</volume>, <issue>Suppl. 1</issue>,
<fpage>4586</fpage>&#x02013;<lpage>4591</lpage><pub-id pub-id-type="pmid">20571116</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Mueller</surname><given-names>S</given-names></name>, <name><surname>Saunier</surname><given-names>K</given-names></name>, <name><surname>Hanisch</surname><given-names>C</given-names></name>, <etal/> (<year>2006</year>) <article-title>Differences in fecal microbiota in
different European study populations in relation to age, gender, and country: a
cross-sectional study</article-title>. <source>Appl Environ Microbiol</source><volume>72</volume>, <fpage>1027</fpage>&#x02013;<lpage>1033</lpage><pub-id pub-id-type="pmid">16461645</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Rajilic-Stojanovic</surname><given-names>M</given-names></name>, <name><surname>Heilig</surname><given-names>HG</given-names></name>, <name><surname>Molenaar</surname><given-names>D</given-names></name>, <etal/> (<year>2009</year>) <article-title>Development and application of the
human intestinal tract chip, a phylogenetic microarray: analysis of universally
conserved phylotypes in the abundant microbiota of young and elderly
adults</article-title>. <source>Environ Microbiol</source><volume>11</volume>, <fpage>1736</fpage>&#x02013;<lpage>1751</lpage><pub-id pub-id-type="pmid">19508560</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>M&#x000e4;kivuokko</surname><given-names>H</given-names></name>, <name><surname>Tiihonen</surname><given-names>K</given-names></name>, <name><surname>Tynkkynen</surname><given-names>S</given-names></name>, <etal/> (<year>2010</year>) <article-title>The effect of age and non-steroidal
anti-inflammatory drugs on human intestinal microbiota composition</article-title>.
<source>Br J Nutr</source><volume>103</volume>, <fpage>227</fpage>&#x02013;<lpage>234</lpage><pub-id pub-id-type="pmid">19703328</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Woodmansey</surname><given-names>EJ</given-names></name>, <name><surname>McMurdo</surname><given-names>ME</given-names></name>, <name><surname>Macfarlane</surname><given-names>GT</given-names></name>, <etal/> (<year>2004</year>) <article-title>Comparison of compositions and
metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and
non-antibiotic-treated elderly subjects</article-title>. <source>Appl Environ Microbiol</source><volume>70</volume>, <fpage>6113</fpage>&#x02013;<lpage>6122</lpage><pub-id pub-id-type="pmid">15466557</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Mariat</surname><given-names>D</given-names></name>, <name><surname>Firmesse</surname><given-names>O</given-names></name>, <name><surname>Levenez</surname><given-names>F</given-names></name>, <etal/> (<year>2009</year>) <article-title>The
<italic>Firmicute</italic>s/<italic>Bacteroidetes</italic> ratio of the human
microbiota changes with age</article-title>. <source>BMC Microbiol</source><volume>9</volume>, 123.</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Fujihashi</surname><given-names>K</given-names></name> &#x00026; <name><surname>Kiyono</surname><given-names>H</given-names></name> (<year>2009</year>) <article-title>Mucosal immunosenescence: new developments and
vaccines to control infectious diseases</article-title>. <source>Trends Immunol</source><volume>30</volume>, <fpage>334</fpage>&#x02013;<lpage>343</lpage><pub-id pub-id-type="pmid">19540811</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Shaw</surname><given-names>AC</given-names></name>, <name><surname>Joshi</surname><given-names>S</given-names></name>, <name><surname>Greenwood</surname><given-names>H</given-names></name>, <etal/> (<year>2010</year>) <article-title>Aging of the innate immune
system</article-title>. <source>Curr Opin Immunol</source><volume>22</volume>, <fpage>507</fpage>&#x02013;<lpage>513</lpage><pub-id pub-id-type="pmid">20667703</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Shaw</surname><given-names>AC</given-names></name>, <name><surname>Panda</surname><given-names>A</given-names></name>, <name><surname>Joshi</surname><given-names>SR</given-names></name>, <etal/> (<year>2011</year>) <article-title>Dysregulation of human Toll-like
receptor function in aging</article-title>. <source>Ageing Res Rev</source><volume>10</volume>, <fpage>346</fpage>&#x02013;<lpage>353</lpage><pub-id pub-id-type="pmid">21074638</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Butcher</surname><given-names>SK</given-names></name>, <name><surname>Chahal</surname><given-names>H</given-names></name>, <name><surname>Nayak</surname><given-names>L</given-names></name>, <etal/> (<year>2001</year>) <article-title>Senescence in innate immune responses:
reduced neutrophil phagocytic capacity and CD16 expression in elderly
humans</article-title>. <source>J Leukoc Biol</source><volume>70</volume>, <fpage>881</fpage>&#x02013;<lpage>886</lpage><pub-id pub-id-type="pmid">11739550</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Gill</surname><given-names>HS</given-names></name>, <name><surname>Darragh</surname><given-names>AJ</given-names></name> &#x00026; <name><surname>Cross</surname><given-names>ML</given-names></name> (<year>2001</year>) <article-title>Optimizing immunity and gut function in the
elderly</article-title>. <source>J Nutr Health Aging</source><volume>5</volume>, <fpage>80</fpage>&#x02013;<lpage>91</lpage><pub-id pub-id-type="pmid">11426287</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Rastall</surname><given-names>RA</given-names></name>, <name><surname>Gibson</surname><given-names>GR</given-names></name>, <name><surname>Gill</surname><given-names>HS</given-names></name>, <etal/> (<year>2005</year>) <article-title>Modulation of the microbial ecology of
the human colon by probiotics, prebiotics and synbiotics to enhance human health: an
overview of enabling science and potential applications</article-title>. <source>FEMS
Microbiol Ecol</source><volume>52</volume>, <fpage>145</fpage>&#x02013;<lpage>152</lpage><pub-id pub-id-type="pmid">16329901</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Tiihonen</surname><given-names>K</given-names></name>, <name><surname>Ouwehand</surname><given-names>AC</given-names></name> &#x00026; <name><surname>Rautonen</surname><given-names>N</given-names></name> (<year>2010</year>) <article-title>Human intestinal microbiota and healthy
ageing</article-title>. <source>Ageing Res Rev</source><volume>9</volume>, <fpage>107</fpage>&#x02013;<lpage>116</lpage><pub-id pub-id-type="pmid">19874918</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Gibson</surname><given-names>GR</given-names></name>, <name><surname>Scott</surname><given-names>KP</given-names></name>, <name><surname>Rastall</surname><given-names>RA</given-names></name>, <etal/> (<year>2011</year>) <article-title>Dietary prebiotics: current status and
new definition</article-title>. <source>Food Sci Tech Bull Funct Foods</source><volume>7</volume>, <fpage>1</fpage>&#x02013;<lpage>19</lpage></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Roberfroid</surname><given-names>MB</given-names></name> (<year>1998</year>) <article-title>Prebiotics and synbiotics: concepts and
nutritional properties</article-title>. <source>Br J Nutr</source><volume>80</volume>, Suppl., <fpage>S197</fpage>&#x02013;<lpage>S202</lpage><pub-id pub-id-type="pmid">9924284</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>van Dokkum</surname><given-names>W</given-names></name>, <name><surname>Wezendonk</surname><given-names>B</given-names></name>, <name><surname>Srikumar</surname><given-names>TS</given-names></name><etal/> (<year>1999</year>) <article-title>Effect of nondigestible oligosaccharides on
large-bowel functions, blood lipid concentrations and glucose absorption in young
healthy male subjects</article-title>. <source>Eur J Clin Nutr</source><volume>53</volume>, <fpage>1</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="pmid">10048793</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Macfarlane</surname><given-names>GT</given-names></name>, <name><surname>Steed</surname><given-names>H</given-names></name> &#x00026; <name><surname>Macfarlane</surname><given-names>S</given-names></name> (<year>2008</year>) <article-title>Bacterial metabolism and health-related effects
of galacto-oligosaccharides and other prebiotics</article-title>. <source>J Appl
Microbiol</source><volume>104</volume>, <fpage>305</fpage>&#x02013;<lpage>344</lpage><pub-id pub-id-type="pmid">18215222</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Watson</surname><given-names>D</given-names></name>, <name><surname>O'Connell Motherway</surname><given-names>M</given-names></name>, <name><surname>Schoterman</surname><given-names>MH</given-names></name>, <etal/> (<year>2013</year>) <article-title>Selective carbohydrate utilization by
lactobacilli and bifidobacteria</article-title>. <source>J Appl Microbiol</source><volume>114</volume>, <fpage>1132</fpage>&#x02013;<lpage>1146</lpage><pub-id pub-id-type="pmid">23240984</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Worthley</surname><given-names>DL</given-names></name>, <name><surname>Le Leu</surname><given-names>RK</given-names></name>, <name><surname>Whitehall</surname><given-names>VL</given-names></name>, <etal/> (<year>2009</year>) <article-title>A human, double-blind,
placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic
supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers
of colorectal cancer</article-title>. <source>Am J Clin Nutr</source><volume>90</volume>, <fpage>578</fpage>&#x02013;<lpage>586</lpage><pub-id pub-id-type="pmid">19640954</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Fujimori</surname><given-names>S</given-names></name>, <name><surname>Gudis</surname><given-names>K</given-names></name>, <name><surname>Mitsui</surname><given-names>K</given-names></name>, <etal/> (<year>2009</year>) <article-title>A randomized controlled trial on the
efficacy of synbiotic <italic>versus</italic> probiotic or prebiotic treatment to
improve the quality of life in patients with ulcerative colitis</article-title>.
<source>Nutrition</source><volume>25</volume>, <fpage>520</fpage>&#x02013;<lpage>525</lpage><pub-id pub-id-type="pmid">19201576</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Alander</surname><given-names>M</given-names></name>, <name><surname>M&#x000e4;tt&#x000f6;</surname><given-names>J</given-names></name>, <name><surname>Kneifel</surname><given-names>W</given-names></name>, <etal/> (<year>2001</year>) <article-title>Effect of galacto-oligosaccharide
supplementation on human faecal microflora and on survival and persistence of
<italic>Bifidobacterium lactis</italic> Bb-12 in the gastrointestinal
tract</article-title>. <source>Int Dairy J</source><volume>11</volume>, <fpage>817</fpage>&#x02013;<lpage>825</lpage></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Gill</surname><given-names>HS</given-names></name>, <name><surname>Rutherfurd</surname><given-names>KJ</given-names></name>, <name><surname>Cross</surname><given-names>ML</given-names></name>, <etal/> (<year>2001</year>) <article-title>Enhancement of immunity in the elderly
by dietary supplementation with the probiotic <italic>Bifidobacterium lactis</italic>
HN019</article-title>. <source>Am J Clin Nutr</source><volume>74</volume>, <fpage>833</fpage>&#x02013;<lpage>839</lpage><pub-id pub-id-type="pmid">11722966</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Vulevic</surname><given-names>J</given-names></name>, <name><surname>Drakoularakou</surname><given-names>A</given-names></name>, <name><surname>Yaqoob</surname><given-names>P</given-names></name>, <etal/> (<year>2008</year>) <article-title>Modulation of the fecal microflora
profile and immune function by a novel <italic>trans</italic>-galactooligosaccharide
mixture (B-GOS) in healthy elderly volunteers</article-title>. <source>Am J Clin Nutr</source><volume>88</volume>, <fpage>1438</fpage>&#x02013;<lpage>1446</lpage><pub-id pub-id-type="pmid">18996881</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Bouhnik</surname><given-names>Y</given-names></name>, <name><surname>Raskine</surname><given-names>L</given-names></name>, <name><surname>Simoneau</surname><given-names>G</given-names></name>, <etal/> (<year>2004</year>) <article-title>The capacity of nondigestible
carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind,
randomized, placebo-controlled, parallel-group, dose&#x02013;response relation
study</article-title>. <source>Am J Clin Nutr</source><volume>80</volume>, <fpage>1658</fpage>&#x02013;<lpage>1664</lpage><pub-id pub-id-type="pmid">15585783</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Ahmed</surname><given-names>M</given-names></name>, <name><surname>Prasad</surname><given-names>J</given-names></name>, <name><surname>Gill</surname><given-names>H</given-names></name>, <etal/> (<year>2007</year>) <article-title>Impact of consumption of different
levels of <italic>Bifidobacterium lactis</italic> HN019 on the intestinal microflora of
elderly human subjects</article-title>. <source>J Nutr Health Aging</source><volume>11</volume>, <fpage>26</fpage>&#x02013;<lpage>31</lpage><pub-id pub-id-type="pmid">17315077</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Hothorn</surname><given-names>T</given-names></name>, <name><surname>Bretz</surname><given-names>F</given-names></name> &#x00026; <name><surname>Westfall</surname><given-names>P</given-names></name> (<year>2008</year>) <article-title>Simultaneous inference in general parametric
models</article-title>. <source>Biomed J</source><volume>50</volume>, <fpage>346</fpage>&#x02013;<lpage>363</lpage></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Langendijk</surname><given-names>PS</given-names></name>, <name><surname>Schut</surname><given-names>F</given-names></name>, <name><surname>Jansen</surname><given-names>GJ</given-names></name>, <etal/> (<year>1995</year>) <article-title>Quantitative fluorescence <italic>in
situ</italic> hybridization of <italic>Bifidobacterium</italic> spp. with
genus-specific 16S rRNA-targeted probes and its application in fecal
samples</article-title>. <source>Appl Environ Microbiol</source><volume>61</volume>, <fpage>3069</fpage>&#x02013;<lpage>3075</lpage><pub-id pub-id-type="pmid">7487040</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Manz</surname><given-names>W</given-names></name>, <name><surname>Amann</surname><given-names>R</given-names></name>, <name><surname>Ludwig</surname><given-names>W</given-names></name>, <etal/> (<year>1996</year>) <article-title>Application of a suite of 16S
rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum
<italic>Cytophaga</italic>&#x02013;<italic>Flavobacter</italic>&#x02013;<italic>Bacteroides</italic>
in the natural environment</article-title>. <source>Microbiology</source><volume>142</volume>, <fpage>1097</fpage>&#x02013;<lpage>1106</lpage><pub-id pub-id-type="pmid">8704951</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Franks</surname><given-names>AH</given-names></name>, <name><surname>Harmsen</surname><given-names>HJ</given-names></name>, <name><surname>Raangs</surname><given-names>GC</given-names></name>, <etal/> (<year>1998</year>) <article-title>Variations of bacterial populations in
human feces measured by fluorescent <italic>in situ</italic> hybridization with
group-specific 16S rRNA-targeted oligonucleotide probes</article-title>. <source>Appl
Environ Microbiol</source><volume>64</volume>, <fpage>3336</fpage>&#x02013;<lpage>3345</lpage><pub-id pub-id-type="pmid">9726880</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Harmsen</surname><given-names>HJM</given-names></name>, <name><surname>Elferich</surname><given-names>P</given-names></name>, <name><surname>Schut</surname><given-names>F</given-names></name>, <etal/> (<year>1999</year>) <article-title>A 16S rRNA-targeted probe for
detection of lactobacilli and enterococci in faecal samples by fluorescent <italic>in
situ</italic> hybridization</article-title>. <source>Microb Ecol Health Dis</source><volume>11</volume>, <fpage>3</fpage>&#x02013;<lpage>12</lpage></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Harmsen</surname><given-names>HJ</given-names></name>, <name><surname>Wildeboer-Veloo</surname><given-names>AC</given-names></name>, <name><surname>Grijpstra</surname><given-names>J</given-names></name>, <etal/> (<year>2000</year>) <article-title>Development of 16S rRNA-based probes
for the <italic>Coriobacterium</italic> group and the <italic>Atopobium</italic> cluster
and their application for enumeration of Coriobacteriaceae in human feces from
volunteers of different age groups</article-title>. <source>Appl Environ Microbiol</source><volume>66</volume>, <fpage>4523</fpage>&#x02013;<lpage>4527</lpage><pub-id pub-id-type="pmid">11010909</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Sghir</surname><given-names>A</given-names></name>, <name><surname>Gramet</surname><given-names>G</given-names></name>, <name><surname>Suau</surname><given-names>A</given-names></name>, <etal/> (<year>2000</year>) <article-title>Quantification of bacterial groups
within human fecal flora by oligonucleotide probe hybridization</article-title>.
<source>Appl Environ Microbiol</source><volume>66</volume>, <fpage>2263</fpage>&#x02013;<lpage>2266</lpage><pub-id pub-id-type="pmid">10788414</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Suau</surname><given-names>A</given-names></name>, <name><surname>Rochet</surname><given-names>V</given-names></name>, <name><surname>Sghir</surname><given-names>A</given-names></name>, <etal/> (<year>2001</year>) <article-title><italic>Fusobacterium
prausnitzii</italic> and related species represent a dominant group within the human
fecal flora</article-title>. <source>Syst Appl Microbiol</source><volume>24</volume>, <fpage>139</fpage>&#x02013;<lpage>145</lpage><pub-id pub-id-type="pmid">11403393</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Costabile</surname><given-names>A</given-names></name>, <name><surname>Kolida</surname><given-names>S</given-names></name>, <name><surname>Klinder</surname><given-names>A</given-names></name>, <etal/> (<year>2010</year>) <article-title>A double-blind, placebo-controlled,
cross-over study to establish the bifidogenic effect of a very-long-chain inulin
extracted from globe artichoke (<italic>Cynara scolymus</italic>) in healthy human
subjects</article-title>. <source>Br J Nutr</source><volume>104</volume>, <fpage>1007</fpage>&#x02013;<lpage>1017</lpage><pub-id pub-id-type="pmid">20591206</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><name><surname>M&#x000e4;kelainen</surname><given-names>H</given-names></name>, <name><surname>Forssten</surname><given-names>S</given-names></name>, <name><surname>Saarinen</surname><given-names>M</given-names></name>, <etal/> (<year>2010</year>) <article-title>Xylo-oligosaccharides enhance the
growth of bifidobacteria and <italic>Bifidobacterium lactis</italic> in a simulated
colon model</article-title>. <source>Benef Microbes</source><volume>1</volume>, <fpage>81</fpage>&#x02013;<lpage>91</lpage><pub-id pub-id-type="pmid">21831753</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><name><surname>Ventura</surname><given-names>M</given-names></name>, <name><surname>Reniero</surname><given-names>R</given-names></name> &#x00026; <name><surname>Zink</surname><given-names>R</given-names></name> (<year>2001</year>) <article-title>Specific identification and targeted
characterization of <italic>Bifidobacterium lactis</italic> from different environmental
isolates by a combined multiplex&#x02013;PCR approach</article-title>. <source>Appl Environ
Microbiol</source><volume>67</volume>, <fpage>2760</fpage>&#x02013;<lpage>2765</lpage><pub-id pub-id-type="pmid">11375192</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><name><surname>Larsen</surname><given-names>CN</given-names></name>, <name><surname>Nielsen</surname><given-names>S</given-names></name>, <name><surname>Kaestel</surname><given-names>P</given-names></name>, <etal/> (<year>2006</year>) <article-title>Dose&#x02013;response study of probiotic
bacteria <italic>Bifidobacterium animalis</italic> subsp <italic>lactis</italic> BB-12
and <italic>Lactobacillus paracasei</italic> subsp <italic>paracasei</italic> CRL-341 in
healthy young adults</article-title>. <source>Eur J Clin Nutr</source><volume>60</volume>, <fpage>1284</fpage>&#x02013;<lpage>1293</lpage><pub-id pub-id-type="pmid">16721394</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><name><surname>Davis</surname><given-names>LM</given-names></name>, <name><surname>Martinez</surname><given-names>I</given-names></name>, <name><surname>Walter</surname><given-names>J</given-names></name>, <etal/> (<year>2010</year>) <article-title>A dose dependent impact of prebiotic
galactooligosaccharides on the intestinal microbiota of healthy adults</article-title>.
<source>Int J Food Microbiol</source><volume>144</volume>, <fpage>285</fpage>&#x02013;<lpage>292</lpage><pub-id pub-id-type="pmid">21059476</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><name><surname>Davis</surname><given-names>LM</given-names></name>, <name><surname>Martinez</surname><given-names>I</given-names></name>, <name><surname>Walter</surname><given-names>J</given-names></name>, <etal/> (<year>2011</year>) <article-title>Barcoded pyrosequencing reveals that
consumption of galactooligosaccharides results in a highly specific bifidogenic response
in humans</article-title>. <source>PLoS ONE</source><volume>6</volume>, e25200.</mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><name><surname>Gill</surname><given-names>HS</given-names></name>, <name><surname>Cross</surname><given-names>ML</given-names></name>, <name><surname>Rutherfurd</surname><given-names>KJ</given-names></name>, <etal/> (<year>2001</year>) <article-title>Dietary probiotic supplementation to
enhance cellular immunity in the elderly</article-title>. <source>Br J Biomed Sci</source><volume>58</volume>, <fpage>94</fpage>&#x02013;<lpage>96</lpage><pub-id pub-id-type="pmid">11440213</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><name><surname>Gill</surname><given-names>HS</given-names></name>, <name><surname>Rutherfurd</surname><given-names>KJ</given-names></name> &#x00026; <name><surname>Cross</surname><given-names>ML</given-names></name> (<year>2001</year>) <article-title>Dietary probiotic supplementation enhances
natural killer cell activity in the elderly: an investigation of age-related
immunological changes</article-title>. <source>J Clin Immunol</source><volume>21</volume>, <fpage>264</fpage>&#x02013;<lpage>271</lpage><pub-id pub-id-type="pmid">11506196</pub-id></mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><name><surname>Arunachalam</surname><given-names>K</given-names></name>, <name><surname>Gill</surname><given-names>HS</given-names></name> &#x00026; <name><surname>Chandra</surname><given-names>RK</given-names></name> (<year>2000</year>) <article-title>Enhancement of natural immune function by
dietary consumption of <italic>Bifidobacterium lactis</italic> (HN019)</article-title>.
<source>Eur J Clin Nutr</source><volume>54</volume>, <fpage>263</fpage>&#x02013;<lpage>267</lpage><pub-id pub-id-type="pmid">10713750</pub-id></mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><name><surname>Schiffrin</surname><given-names>EJ</given-names></name>, <name><surname>Rochat</surname><given-names>F</given-names></name>, <name><surname>Link-Amster</surname><given-names>H</given-names></name>, <etal/> (<year>1995</year>) <article-title>Immunomodulation of human blood cells
following the ingestion of lactic acid bacteria</article-title>. <source>J Dairy Sci</source><volume>78</volume>, <fpage>491</fpage>&#x02013;<lpage>497</lpage><pub-id pub-id-type="pmid">7782506</pub-id></mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><name><surname>Chiang</surname><given-names>BL</given-names></name>, <name><surname>Sheih</surname><given-names>YH</given-names></name>, <name><surname>Wang</surname><given-names>LH</given-names></name>, <etal/> (<year>2000</year>) <article-title>Enhancing immunity by dietary
consumption of a probiotic lactic acid bacterium (<italic>Bifidobacterium
lactis</italic> HN019): optimization and definition of cellular immune
responses</article-title>. <source>Eur J Clin Nutr</source><volume>54</volume>, <fpage>849</fpage>&#x02013;<lpage>855</lpage><pub-id pub-id-type="pmid">11114680</pub-id></mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><name><surname>Foligne</surname><given-names>B</given-names></name>, <name><surname>Nutten</surname><given-names>S</given-names></name>, <name><surname>Grangette</surname><given-names>C</given-names></name>, <etal/> (<year>2007</year>) <article-title>Correlation between <italic>in
vitro</italic> and <italic>in vivo</italic> immunomodulatory properties of lactic acid
bacteria</article-title>. <source>World J Gastroenterol</source><volume>13</volume>, <fpage>236</fpage>&#x02013;<lpage>243</lpage><pub-id pub-id-type="pmid">17226902</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><name><surname>Franceschi</surname><given-names>C</given-names></name>, <name><surname>Capri</surname><given-names>M</given-names></name>, <name><surname>Monti</surname><given-names>D</given-names></name>, <etal/> (<year>2007</year>) <article-title>Inflammaging and anti-inflammaging: a
systemic perspective on aging and longevity emerged from studies in
humans</article-title>. <source>Mech Ageing Dev</source><volume>128</volume>, <fpage>92</fpage>&#x02013;<lpage>105</lpage><pub-id pub-id-type="pmid">17116321</pub-id></mixed-citation></ref></ref-list></back></article>